HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1

被引:15
|
作者
Quesnel-Vallieres, Mathieu [1 ,4 ]
Lemay, Mireille [2 ,5 ]
Lapointe, Normand [2 ,5 ]
Martin, Steven R. [3 ,5 ]
Soudeyns, Hugo [1 ,4 ,5 ]
机构
[1] CHU St Justine, Ctr Rech, Unite Immunopathol Virale, Montreal, PQ H3T 1C5, Canada
[2] CHU St Justine, Ctr Rech, Ctr Maternal & Infantile SIDA, Montreal, PQ H3T 1C5, Canada
[3] CHU St Justine, Ctr Rech, Serv Gastroenterol & Nutr, Montreal, PQ H3T 1C5, Canada
[4] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3C 3J7, Canada
关键词
Hepatitis C virus; Coinfection; Pediatrics; Mother-to-child transmission; Interferon; Ribavirin;
D O I
10.1016/j.jcv.2008.06.019
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Two children who acquired hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infection by mother-to-child transmission were monitored during interferon alfa-2b and ribavirin treatment. In Patient C1, CD4(+) T cell counts were within normal range and HIV-1 viral load was undetectable. HCV viral load declined slightly following treatment initiation while novel variants rapidly emerged, indicative of quasispecies diversification. In Patient C2, CD4(+) T cell counts were low and HIV-1 replication was not fully controlled by antiretroviral therapy. HCV viral load rose during treatment and a striking conservation of the variant spectrum was observed. In both cases, there was no decline in quasispecies complexity following treatment initiation and sustained virological response was not achieved. These results suggest that reduction in quasispecies complexity, which is observed in adult responders following interferon treatment, may be mechanistically unrelated with evolution of the variant profile and/or selective pressure exerted on HCV. (C) 2008 Elsevier B.V. All rights reserved
引用
收藏
页码:236 / 240
页数:5
相关论文
共 50 条
  • [31] The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV
    Opravil, Milos
    Rodriguez-Torres, Maribel
    Rockstroh, Juergen
    Snoeck, Eric
    Chung, Raymond T.
    Tietz, Andreas
    Torriani, Francesca J.
    HIV CLINICAL TRIALS, 2012, 13 (01): : 33 - 45
  • [32] Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaiVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1
    Manns, Michael P.
    Poordad, Fred
    Bacon, Bruce R.
    Bruno, Savino
    Esteban, Rafael
    Silva, Marcelo O.
    Buti, Maria
    Burroughs, Margaret
    Sniukiene, Vilma
    Boparai, Navdeep
    Brass, Cliflord A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    GASTROENTEROLOGY, 2011, 140 (05) : S942 - S942
  • [33] Comparison of 2 doses of PEG-interferon alfa-2b plus weight based ribavirin for treatment of previously untreated patients with genotype 1 HCV infection
    Cox, PP
    Do, H
    Carithers, RL
    HEPATOLOGY, 2004, 40 (04) : 342A - 342A
  • [34] Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection - Reply
    Mangia, A
    Andriulli, A
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11): : 1183 - 1183
  • [35] Improved Treatment for Primary HIV Infection by Interferon-Alfa Therapy? Does HCV Treatment in HIV/HCV Coinfected Patients Help Us to Test This Hypothesis?
    zur Wiesch, Julian Schulze
    van Lunzen, Jan
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (02): : 362 - 362
  • [36] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1
    Manns, M. P.
    Poordad, F.
    Bacon, B. R.
    Bruno, S.
    Esteban, R.
    Silva, M.
    Buti, M.
    Burroughs, M.
    Sniukiene, V.
    Boparai, N.
    Brass, C. A.
    Albrecht, J. K.
    Bronowicki, J. -P.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S182 - S183
  • [37] Treatment with combination peginterferon alfa-2b and ribavirin of recurrent hepatitis C in liver transplant recipients nonresponsive to interferon alfa-2b and ribavirin
    Samanta, A
    Mandalapu, A
    Fisher, A
    Wilson, D
    de la Torre, A
    Klein, KM
    Koneru, B
    GASTROENTEROLOGY, 2005, 128 (04) : A455 - A456
  • [38] Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b
    De Blasi, T.
    Marucco, D. Aguilar
    Cariti, G.
    Maiello, A.
    De Rosa, F. G.
    Di Perri, G.
    INFECTION, 2008, 36 (03) : 285 - 287
  • [39] Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy
    Torres, Harrys A.
    Bull, Lara
    Arduino, Roberto C.
    Barnett, Ben J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (06): : 1334 - 1335
  • [40] Cryoglobulinemia-Related Vasculitis During Effective Anti-HCV Treatment with PEG-Interferon alfa-2b
    T. De Blasi
    D. Aguilar Marucco
    G. Cariti
    A. Maiello
    F. G. De Rosa
    G. Di Perri
    Infection, 2008, 36 : 285 - 287